ABSTRACT
Aim of the Review:
The 5 year estimated survival outcomes for muscle invasive bladder cancer was demonstrated at the interval of 60-70% in best series The aim of this review is to demonstrate the efficacy of neoadjuvant chemotherapy in muscle invasive bladder cancer.
New Findings:
The meta-analyses demonstrated a mean 5% contribution of cisplatin based chemotherapy regimes for the survival of these patients. Successful local treatment is crucial for this well tolerated therapy.
Conclusion:
Neoadjuvant chemotherapy enhances survival with reasonable toxicity and mortality rates.
